Form 4: Allogene Therapeutics Director Sells Over 36,000 Shares Under Pre-Arranged Trading Plan

Deborah M. Messemer, a Director at Allogene Therapeutics, Inc., reported the sale of 36,885 shares of common stock for approximately $52,376 under a Rule 10b5-1 trading plan.

Summary

• Deborah M. Messemer, a Director of Allogene Therapeutics, Inc. (ALLO), reported the sale of 36,885 shares of the company's common stock.
• The transaction occurred on June 10, 2025, at a weighted average price of $1.42 per share.
• The shares were sold in multiple transactions ranging from $1.38 to $1.445 per share.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Ms. Messemer on August 30, 2024.
• Following this transaction, Ms. Messemer beneficially owns 107,431 shares of Allogene Therapeutics common stock directly.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative to neutral. While the sale was under a pre-arranged 10b5-1 plan, which mitigates the immediate negative signal, a director selling shares is generally not viewed as a positive indicator for investors, especially given the volume.

Negatives

• The sale of shares by a director, even under a pre-arranged plan, can sometimes be perceived negatively by investors as it may suggest a lack of confidence or simply add selling pressure to the stock.

Risks

• Insider selling, particularly by a director, can be interpreted by the market as a potential signal regarding the company's future prospects, which could lead to negative sentiment or downward pressure on the stock price.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a standard disclosure of an insider transaction and does not provide broader industry context or trends. It reflects an individual director's stock activity within the biotechnology sector.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a signal, potentially influencing their perception of the stock's value or future performance. The sale also adds shares to the market, which could contribute to selling pressure.

Key Dates

Keywords

Allogene Therapeutics, ALLO, Form 4, Insider Trading, Stock Sale, Director, Deborah M. Messemer, Rule 10b5-1 Plan